IL10 and melanoma: Furthermore, flow cytometric analysis demonstrated that STAT3 inhibitor with PD-1 treatment weakened the secretion of TGF-β and IL-10 on Treg cells compared to anti-PD-1-treated melanoma mice, implying an enhanced anti-tumor immunity (Figures 6F, G).